Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (0K1R.L) Financial Performance & Income Statement Overview
Analyze Viridian Therapeutics, Inc. (0K1R.L) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Viridian Therapeutics, Inc. (0K1R.L) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Viridian Therapeutics, Inc. 0K1R.L financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $72000.00 | $72000.00 | $86000.00 | $72000.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $5.79M |
| Gross Profit | $72000.00 | -$51000.00 | $86000.00 | -$5.72M |
| Gross Profit Ratio | $1.00 | -$0.71 | $1.00 | -$79.43 |
| R&D Expenses | $76.83M | $71.96M | $69.16M | $56.19M |
| SG&A Expenses | $17.10M | $15.58M | $14.41M | $16.07M |
| Operating Expenses | $93.94M | $87.54M | $83.57M | $72.26M |
| Total Costs & Expenses | $93.94M | $93.68M | $83.57M | $72.26M |
| Interest Income | $7.54M | $8.61M | $7.79M | $7.79M |
| Interest Expense | $586000.00 | $858000.00 | $1.004M | $597000.00 |
| Depreciation & Amortization | $117000.00 | $123000.00 | $130000.00 | $142000.00 |
| EBITDA | -$86.21M | -$78.74M | -$75.56M | -$63.85M |
| EBITDA Ratio | -$1197.35 | -$1093.67 | -$878.55 | -$886.86 |
| Operating Income | -$93.87M | -$87.47M | -$83.48M | -$72.19M |
| Operating Income Ratio | -$1303.69 | -$1214.89 | -$970.70 | -$1002.60 |
| Other Income/Expenses (Net) | $6.95M | $7.75M | $6.79M | $7.19M |
| Income Before Tax | -$86.91M | -$79.72M | -$76.69M | -$64.99M |
| Income Before Tax Ratio | -$1207.11 | -$1107.29 | -$891.73 | -$902.68 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$86.91M | -$79.72M | -$76.69M | -$64.99M |
| Net Income Ratio | -$1207.11 | -$1107.29 | -$891.73 | -$902.68 |
| EPS | -$0.87 | -$0.81 | -$1.15 | -$1.02 |
| Diluted EPS | -$0.87 | -$0.81 | -$1.15 | -$1.02 |
| Weighted Avg Shares Outstanding | $81.34M | $80.05M | $66.42M | $63.85M |
| Weighted Avg Shares Outstanding (Diluted) | $81.34M | $80.05M | $66.42M | $63.85M |
Over the last four quarters, Viridian Therapeutics, Inc.'s revenue moved from $72000.00 in Q2 2024 to $72000.00 in Q1 2025. Operating income in Q1 2025 was -$93.87M, with a strong operating margin of -130369%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Viridian Therapeutics, Inc. remained robust at -$86.21M, reflecting operational efficiency. Net income dropped to -$86.91M, with an EPS of -$0.87. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan